Skip to main content

Table 2 Percentage of patients achieving a response at Week 12 and Week 52 (NRI)

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

n (%)

Week 12

Week 52

Placebo

+ NBBM

(n = 158)

CZP 200 mg Q2W

+ NBBM

(n = 159)

Placebo

+ NBBM

(n = 158)

CZP 200 mg Q2W

+ NBBM

(n = 159)

ASDAS-MI

10 (6.3)

56 (35.2)

11 (7.0)

75 (47.2)

ASAS40

18 (11.4)

76 (47.8)

25 (15.8)

90 (56.6)

BASDAI50

23 (14.6)

68 (42.8)

19 (12.0)

88 (55.3)

ASDAS-ID

2 (1.3)

26 (16.4)

6 (3.8)

44 (27.7)

  1. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, NRI non-responder imputation, Q2W every 2 Weeks